Mesa Laboratories (NASDAQ:MLAB) Releases Quarterly Earnings Results, Misses Expectations By $0.25 EPS

Mesa Laboratories (NASDAQ:MLAB) posted its earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.78 by ($0.25), Zacks reports. Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.The firm had revenue of $63.72 million for the quarter, compared to analyst estimates of $65.21 million. During the same period in the previous year, the company posted ($1.31) EPS.

Mesa Laboratories Stock Performance

Shares of MLAB opened at $106.66 on Wednesday. The stock has a 50-day simple moving average of $97.29 and a 200-day simple moving average of $88.13. The company has a debt-to-equity ratio of 0.86, a quick ratio of 1.45 and a current ratio of 0.44. The stock has a market capitalization of $588.76 million, a PE ratio of 88.88 and a beta of 0.94. Mesa Laboratories has a 1 year low of $55.45 and a 1 year high of $111.29.

Mesa Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 15th. Shareholders of record on Friday, May 29th will be given a $0.16 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $0.64 dividend on an annualized basis and a yield of 0.6%. Mesa Laboratories’s dividend payout ratio (DPR) is currently 53.33%.

Insider Transactions at Mesa Laboratories

In other news, Director Shiraz Shabanali Ladiwala bought 3,500 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The shares were purchased at an average cost of $72.23 per share, for a total transaction of $252,805.00. Following the completion of the purchase, the director owned 8,523 shares of the company’s stock, valued at approximately $615,616.29. This represents a 69.68% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director R Tony Tripeny bought 1,315 shares of Mesa Laboratories stock in a transaction that occurred on Tuesday, March 10th. The stock was purchased at an average cost of $76.00 per share, for a total transaction of $99,940.00. Following the acquisition, the director owned 5,398 shares of the company’s stock, valued at $410,248. This represents a 32.21% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders purchased 6,116 shares of company stock valued at $452,076. 4.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Mesa Laboratories

Institutional investors have recently modified their holdings of the company. Invesco Ltd. grew its stake in shares of Mesa Laboratories by 11.7% during the fourth quarter. Invesco Ltd. now owns 12,845 shares of the medical instruments supplier’s stock worth $1,008,000 after purchasing an additional 1,350 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Mesa Laboratories during the 4th quarter worth about $989,000. Tudor Investment Corp ET AL boosted its position in shares of Mesa Laboratories by 332.5% during the 4th quarter. Tudor Investment Corp ET AL now owns 27,426 shares of the medical instruments supplier’s stock worth $2,153,000 after acquiring an additional 21,085 shares in the last quarter. Quadrature Capital Ltd purchased a new position in shares of Mesa Laboratories in the 4th quarter valued at about $1,062,000. Finally, Numerai GP LLC raised its position in shares of Mesa Laboratories by 313.0% during the 4th quarter. Numerai GP LLC now owns 14,909 shares of the medical instruments supplier’s stock worth $1,170,000 after acquiring an additional 11,299 shares in the last quarter. 90.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on MLAB shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of Mesa Laboratories in a research note on Monday, May 4th. Wells Fargo & Company lifted their price objective on shares of Mesa Laboratories from $83.00 to $94.00 and gave the company an “equal weight” rating in a report on Wednesday, February 4th. Finally, Wall Street Zen raised shares of Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 7th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $94.00.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.